MET and breast carcinoma: Concerning drug resistance, Yue et al. revealed that miR-182 binds to MET in breast cancer cells and suppresses the cell's ability to tolerate trastuzumab, therefore reducing the invasion and migration capability of trastuzumab-resistant cells through MET-dependent PI3K/AKT/mTOR signaling pathways (Yue and Qin, 2019).